$PFE Headlines Large-caps can boost your portfolio at

New Post Public Reply Private Reply Replies (0) Message Board

Nov 25, 2013 at 6:33 PM

$PFE Headlines

Large-caps can boost your portfolio at year-end 2:58 p.m. Nov. 22, 2013 - Mark Hulbert
Stock market live blog: S&P 500 record, Twitter options, China ETFs (Recap) 11:39 a.m. Nov. 18, 2013 - blogs.marketwatch.com
The best stock sector for your money now 6:01 a.m. Nov. 15, 2013 - Howard Gold
Where's the market oopmh? Cisco and a turnaround on Exxon Mobil 8:45 a.m. Nov. 13, 2013 - blogs.marketwatch.com
How to invest in and buy a bitcoin 3:22 p.m. Nov. 12, 2013 - blogs.marketwatch.com
Pfizer's Rapamune doesn't meet primary endpoint 8:51 a.m. Nov. 8, 2013 - MarketWatch.com
Is this March 2000 all over again? 3:07 p.m. Nov. 7, 2013 - Mark Hulbert
Newscast: The Dow and S&P 500 set new record highs 6:31 p.m. Oct. 29, 2013 - MarketWatch
Energy stocks gain; BP shares rally on earnings 5:12 p.m. Oct. 29, 2013 - Claudia Assis
S&P 500, Dow industrials close at record highs 4:41 p.m. Oct. 29, 2013 - Victor Reklaitis
Newscast: Wall Street heads higher and sets record 4:33 p.m. Oct. 29, 2013 - MarketWatch
U.S. stocks open higher; Pfizer rises 1% 9:36 a.m. Oct. 29, 2013 - Victor Reklaitis
Stock futures up slightly ahead of Fed meeting 9:04 a.m. Oct. 29, 2013 - Sara Sjolin
Pfizer profit falls, adjusts full-year views 7:24 a.m. Oct. 29, 2013 - MarketWatch.com
Pfizer net falls, adjusts full-year earnings range 7:18 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 revenue down 2% to $12.64 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 profit falls 19% to $2.59 billion 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Pfizer Q3 EPS falls to $0.39; adj. EPS up to $0.58 7:04 a.m. Oct. 29, 2013 - Saumya Vaishampayan
Cat's warning sign, a Michael Kors pop and the surf pounds Portugal 6:11 a.m. Oct. 29, 2013 - blogs.marketwatch.com
Apple, LinkedIn, Pfizer, Michael Kors: hot stocks 5:30 a.m. Oct. 29, 2013 - Ben Eisen

Can Pfizer Continue to Outperform? 5:29 p.m. Today - Wall St. Cheat Sheet
Most popular hedge fund shorts according to Goldman monitor 4:03 p.m. Today - Seeking Alpha
Pfizer: 3 Different Insiders Have Sold Shares During The Last 30 Days 3:54 p.m. Today - Seeking Alpha
Glaxo Shares Rise on Tivicay News - Analyst Blog 2:13 p.m. Today - Zacks.com
Rexahn's Akt-1 Inhibitor To Begin Phase II Trials For Kidney Treatment 1:47 p.m. Today - Seeking Alpha
Pfizer Subsidiary to Take Over Local Affiliate Wyeth in India 1:23 p.m. Today - Wall St. Cheat Sheet
$112 Billion Fund Down On Stocks: Except These 12:05 p.m. Today - Seeking Alpha
Pfizer to Wed Indian Operations and Wyeth’s India Unit 11:44 a.m. Today - Wall St. Cheat Sheet
Stock Market News for November 25, 2013 - Market News 10:06 a.m. Today - Zacks.com
Pfizer's Indian unit to take full control of Wyeth 4:03 a.m. Nov. 24, 2013 - Seeking Alpha
Pfizer Feels the Heat From Novartis 4:14 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Neurotrope: Intriguing Play On Alzheimer's 3:58 p.m. Nov. 22, 2013 - Seeking Alpha
Novartis ambushes Pfizer with breast cancer treatment 3:06 p.m. Nov. 22, 2013 - Seeking Alpha
4 Biotech Stocks Making Big Moves 12:47 p.m. Nov. 22, 2013 - Wall St. Cheat Sheet
Two Small-Cap Biotechs to Watch 12:00 p.m. Nov. 22, 2013 - RealMoney.com
Wall Street Breakfast: Must-Know News 6:33 a.m. Nov. 22, 2013 - Seeking Alpha
Novartis to repurchase $5B in shares over two years 4:24 a.m. Nov. 22, 2013 - Seeking Alpha
Pfizer Gets FDA Nod for Xalkori Lung Cancer Drug and 2 Other Dow Movers to Watch 1:53 p.m. Nov. 21, 2013 - Wall St. Cheat Sheet
Data on Amgen's Pipeline Candidates - Analyst Blog 11:50 a.m. Nov. 21, 2013 - Zacks.com
Stock Market News for November 21, 2013 - Market News 10:06 a.m. Nov. 21, 2013 - Zacks.com

Just in Time for Peak Travel Season, Introducing New Robitussin(R) DM Max Liquid-Filled Capsules 9:00 a.m. Today - BusinessWire
Upcoming Conference Schedules, Orphan Drug Designations and Stock Price Updates - Research Report on Pfizer, ICU Medical, CONMED, Gentium, and Repros Therapeutics 8:00 a.m. Today - PR Newswire
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV 9:00 a.m. Nov. 22, 2013 - PR Newswire
Pfizer's XALKORI(R) Granted Regular FDA Approval 11:00 a.m. Nov. 21, 2013 - BusinessWire
Pfizer and GSK to Initiate Study of Novel Combination Therapy in Patients with Melanoma 8:00 a.m. Nov. 21, 2013 - BusinessWire
FDA Approvals, Stock Price Movements, and Study Results - Research Report on Pfizer, Celgene, Merck, Quest Diagnostics, and Pharmacyclics 8:00 a.m. Nov. 21, 2013 - PR Newswire
Lithera Announces Appointment of Dermatology and Aesthetics Authority Dr. Lincoln Krochmal as Chief Medical Officer 7:00 a.m. Nov. 21, 2013 - GlobeNewswire
Notes Redemption, Upcoming Presentations, and Manufacturing Investments - Research Report on Pfizer, Baxter, Lilly, UnitedHealth Group, and Align Technology 8:00 a.m. Nov. 19, 2013 - PR Newswire
Pfizer Announces FDA Approval of Supplemental Application to Expand XELJANZ(R) (tofacitinib citrate) Labeling to Include Additional Patient-Reported Outcomes Data for Adults with Moderately to Severely Active Rheumatoid Arthritis 4:47 p.m. Nov. 18, 2013 - BusinessWire
Today's Research: Pfizer Inc., Merck & Co. Inc., AbbVie Inc., and Zogenix Inc. 6:21 p.m. Nov. 14, 2013 - PR Newswire
Pfizer Subsidiary, Wyeth LLC, To Redeem 5.500% Notes Due February 1, 2014 8:30 a.m. Nov. 14, 2013 - BusinessWire
Acquisitions, Clinical Trial Results and Stock Price Movements - Research Report on ViroPharma, Pfizer, Alkermes, Tenet, and ResMed 8:00 a.m. Nov. 14, 2013 - PR Newswire
Athersys Recognized Among Fastest Growing Companies in North America on Deloitte's 2013 Technology Fast 500(TM) 2:00 p.m. Nov. 13, 2013 - GlobeNewswire
Critical Alerts For Micron Technology, Sarepta Therapeutics, Alliance Fiber Optic Products, Pfizer, and KB Home Released By InvestorsObserver 9:31 a.m. Nov. 11, 2013 - PR Newswire
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R) (sirolimus) In Renal Transplant Recipients 8:00 a.m. Nov. 8, 2013 - BusinessWire
The Global Revolution in Biotechnology and the Impact of Regenerative Medicine 9:53 a.m. Nov. 7, 2013 - ACCESSWIRE
GlycoMimetics to Present Five Abstracts at 2013 American Society of Hematology Annual Meeting 9:11 a.m. Nov. 7, 2013 - BusinessWire
FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo, Arena, Wright Medical, and Ophthotech 8:00 a.m. Nov. 7, 2013 - PR Newswire
2013 mHealth Summit Launches First Pharma and Life Sciences Roundtable 2:31 p.m. Nov. 6, 2013 - PR Newswire
Former U.S. President Jimmy Carter And Pfizer Celebrate 15-Year Effort To Help End Blinding Trachoma As A Public Health Concern 12:32 p.m. Nov. 5, 2013 - BusinessWire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beverly Hills MD's Dermal Cream Wins Key Beauty Award

A Surprise Win in the Beauty World Who doesn't love an underdog story, right? Beverly Hills MD has slid into the limelight with their Dermal Repair Complex snagging the award for 'Beauty Product of the Year.' Talk about sending shockwaves through the beauty industry! Now, these guys might not be a household name yet, but you better believe they've got everyone's attention...

Curaleaf Expands in Florida Amid Rising Cannabis Demand

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

AI Platform Suno Sued for Exploiting Artists' Identities

AI and the Music Business: A Legal Storm Brews Well, it looks like the music world’s hitting a rough patch with AI in the crosshairs. We've got Korein Tillery, a heavyweight in the legal arena, throwing down the gauntlet against Suno, an AI music-generation platform. Folks, welcome to the battleground where art meets tech and identity theft takes a whole new meaning....

Rackspace Lawsuit Deadline: Investors Must Take Action

Rackspace's Legal Predicament: Time for Action Alright folks, if you're holding shares of Rackspace Technology (NASDAQ:RXT), it’s time to sit up and pay attention. This is about more than bad PR or a temporary hiccup in the stock price—this is serious business. We’ve got until September 28, 2026, to decide if we’re in or out on this class action lawsuit train....

Clinical Trials Services Market Set for Big Growth

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

Art and Science Blend in Dr. De La Cruz's Approach

Redefining Aesthetic Surgery: An Artistic Approach The world of plastic surgery is often seen through the lens of beauty and symmetry, but for Dr. Emmanuel De La Cruz, it's like staring into a whole different universe. This Houston-based plastic surgeon isn't just removing fat—he's reshaping the human canvas with the eye of a sculptor. Beyond the Standard Cut and Snip...

IVD Study Success: Hybrid Monitoring Boosts Oversight

New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...

CAPR Faces Lawsuit and FDA Delay: Investor Alert

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Orbis Celebrates 20 Years of Eye Care in Macau

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Faruqi & Faruqi Urge Wix Investors to Act Now

Ticking Clock for Wix Investors' Legal Moves The buzz in the stock market is louder than a bull on Wall Street, especially if you're tangled up with Wix.com Ltd. (NASDAQ: WIX). We've got Faruqi & Faruqi, LLP laying down serious advice: move fast or maybe lose your spot in line. The deadline to noodle over your position as a lead plaintiff in their federal securities class...